糖尿病患者中SGLT-2抑制剂的安全性接受了针对功能的选择性皮肤冠状动脉干预:SAFE-PCI试点研究
Mateus Paiva Marques Feitosa1,2, Eduardo Gomes Lima3, Alexandre Antônio Cunha Abizaid3
1Instituto Do Coração (InCor), Hospital das Clínicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil. mateusfeitosa@gmail.com.
Diabetology & metabolic syndrome
|June 26, 2023
概括
在接受皮肤冠状动脉干预 (PCI) 的2型糖尿病患者中,empagliflozin的使用对功能是安全的. 这项研究发现,在服用empagliflozin和不服用empagliflozin的患者之间,损伤生物标志物或肌素水平没有显著差异.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 内分泌学 在内分泌学.
背景情况:
- 穿皮冠状动脉干预 (PCI) 是改善生活质量的常见程序.
- -葡萄糖携带载体-2 抑制剂 (SGLT2i) 可能会引起人们对脱水和急性损伤 (AKI) 的担忧.
- 没有关于在PCI期间继续SGLT2i的确定的准则.
研究的目的:
- 评估empagliflozin在接受选择性PCI的糖尿病患者中的安全性.
- 评估empagliflozin对PCI后功能生物标志物的影响.
主要方法:
- 一项前性随机试点研究 (SAFE-PCI试验) 涉及42名患者.
- 每天25毫克的empagliflozin至少在PCI前15天服用,并在随访期间继续使用.
- 在PCI后监测了血清中性纤维糖酶相关的利波卡林 (NGAL) 和肌素水平.
主要成果:
- 在PCI后48小时,empagliflozin和对照组之间在NGAL或肌素水平上没有显著差异.
- 在两组中,对比诱导的AKI (CI-AKI) 的发生率相似 (13.6%对10.0%).
- 在SGLT2i组的初始肌激素增加在48小时后没有持续下去.
结论:
- 在接受选择性PCI的2型糖尿病患者中,empagliflozin的使用对功能是安全的.
- 这些发现表明,SGLT2i可以在这个患者群体中安全地继续使用.
- 进一步的研究可能会在更大的试验中证实这些安全性发现.
相关概念视频
Cardiac Catheterization I: Pre-Procedure Overview
73
Cardiac catheterization is an invasive diagnostic technique used to identify and evaluate structural and functional diseases of the heart and major blood vessels. This technique diagnoses congenital heart disease, coronary artery disease, valvular heart disease, and coronary spasms and assesses ventricular function. It helps guide treatment decisions, including the need for revascularization procedures like percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) and...
73
Acute Kidney Injury IV: Diagnostic Studies and Prevention
40
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
40
Dipeptidyl Peptidase 4 Inhibitors
214
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
214
Kidney Transplant I: Introduction
29
A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
29
Kidney Transplant II: Surgical Procedure
36
Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living...
36
Acute Kidney Injury V: Interprofessional Care
30
Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
30


